Nicholas Short, M.D.
Stories this photo appears in:
Combination therapy results in 98% response rate for some newly diagnosed leukemia patients
Lower-dose chemotherapy plus monoclonal antibodies highly effective for older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.
